Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Repurposing drugs for the treatment of acute GvHD

Shernan Holtan • 25 Apr 2022
The 2022 Tandem Meetings
General Human chorionic gonadotropin

Shernan Holtan, MD, University of Minnesota, Minneapolis, MN, talks on the growing use of regenerative treatment strategies in acute graft-versus-host disease (aGvHD). A recent Phase II study (NCT02525029) has shown that repurposing existing drugs such as human chorionic gonadotropin represents a promising option to improve the outcomes of patients with GvHD whilst decreasing the cost of treatment. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Shernan Holtan

0:43
Post-transplant cyclophosphamide, tacrolimus, and MMF for GvHD in the myeloablative setting
Shernan Holtan • 10 Dec 2022
1:05
Unmet needs in GvHD & the promise of regenerative medicine
Shernan Holtan • 10 Dec 2022
0:58
How GvHD impacts patient quality of life
Shernan Holtan • 10 Dec 2022
1:15
ASH 2022 LBA: post-transplant cyclophosphamide, tacrolimus & MMF for GvHD prophylaxis in RIC
Shernan Holtan • 10 Dec 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals